2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM: Abstract Number: 2026

Pneumococcal Vaccination Rates: Improving Safety in Immunocompromised Patients

Measures and Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 2365

Poor Cardiovascular Risk Management in Rheumatoid Arthritis Patients Despite an Explicit Cardiovascular Risk Management Program

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2061

Population-Specific Factors Associated with Fractional Excretion of Uric Acid

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2025

Potential Clinical Utility of Manu-Scan, the Novel Optical Molecular Imaging, in Patients with Hand Rheumatoid Arthritis

ARHP Imaging of Rheumatic Diseases Poster

9:00AM-11:00AM: Abstract Number: 2501

Potential Differences in Axial Spondyloarthritis Disease Activity Categorization Using Different Minimum Values for High-Sensitivity CRP in Ankylosing Spondylitis Disease Activity Score Calculation and Different Definitions of Disease Flare

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

9:00AM-11:00AM: Abstract Number: 2041

Practice Improvement Utilizing Six Sigma and Health Informatics in an Academic Setting

Measures and Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 2027

Pre-Visit Planning Improves Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematosus

Measures and Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 2625

Predicting Flares in Patients with Stable Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

9:00AM-11:00AM: Abstract Number: 2024

Prediction of Response to Certolizumab-Pegol in Rheumatoid Arthritis By Functional MRI of the Brain – an Interim Analysis of an Ongoing Investigator Initiated Phase III Trial

Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2138

Predictive Factors for Achievement of Sustained Remission with Polymyositis/Dermatomyositis: A Retrospective Single Center Cohort Study in Japan

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 2300

Predictive Value of Magnetic Resonance Imaging in Patients with Juvenile Idiopathic Arthritis in Clinical Remission

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

9:00AM-11:00AM: Abstract Number: 2073

Predictors for Clinically Diagnosed Gout – Results from 30 Years Follow-up of the Malmö Preventive Project Cohort in Southern Sweden

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2251

Preferences for Physical Activity: A Discrete Choice Experiment in People with Chronic Knee Pain

Patient Outcomes, Preferences, and Attitudes Poster III

9:00AM-11:00AM: Abstract Number: 2646

Premature Senescence of Naive CD4+ T-Cells in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1969

Prevalence and Predictive Value over 16 Years of Serum Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies in the General Population

Epidemiology and Public Health Poster III: Rheumatic Disease Risk and Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].